Vitrakvi (larotrectinib) - Bayer
Zelboraf (vemurafenib) - Roche
samotolisib (LY3023414) - Eli Lilly
Tibsovo (ivosidenib) - Servier
Ensacove (ensartinib) - Betta Pharma
Ibrance (palbociclib) - Pfizer
Balversa (erdafitinib) - J&J
Zarnestra (tipifarnib) - Kura Oncology
ulixertinib (BVD-523) - BioMed Valley Discoveries
naltrexone implant (OLANI) - Go Medical
Lynparza (olaparib) - Merck (MSD), AstraZeneca
Koselugo (selumetinib) - AstraZeneca
Retevmo (selpercatinib) - Eli Lilly
Tazverik (tazemetostat) - Ipsen
http://clinicaltrials.gov/ct2/show/NCT03155620
 
Jan 17, 2026
 
Next